ArticleBrain pathology (Zurich, Switzerland)2026
Meflin/ISLR is a meningeal cell-specific marker involved in the development of meninges and meningioma progression.
Article in Brain pathology (Zurich, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Modeling meningioma in vitro in the omics era.Human cell · 2026Review
- The Wnt signaling networks in higher-grade meningiomas: from molecular pathogenesis to therapeutic innovation.Cancer cell international · 2026Review
- Meflin/ISLR is a meningeal cell-specific marker involved in the development of meninges and meningioma progression.Brain pathology (Zurich, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The meninges, which originate from the neural crest cells and mesoderm, play crucial roles in the formation, protection, and homeostasis of the central nervous system. Meningiomas, which arise from the meninges, are the most common primary intracranial tumors, and their recurrence and malignant transformation represent major clinical challenges. Recent studies have identified mesenchymal stromal cell- and fibroblast-expressing Linx paralogue (Meflin), as being expressed in the meninges, but its role in meningeal development and meningioma pathophysiology remains poorly understood. In this study, we investigated the expression patterns of Meflin during meningeal development and in meningioma tissues. Meflin expression was detected in the head of a Meflin reporter mouse line at approximately 11.5 days of embryonic life, suggesting its involvement in early meningeal development. Lineage-tracing experiments revealed that Meflin mRNA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.